Discovery of WNT9B Gene Mutation Significantly Increases Prostate Cancer Risk
/0 Comments/in Observational/by MaxEcDNA and Prostate Cancer: A New Frontier in Understanding Resistance
/0 Comments/in Preclinical Research/by MaxHydrogel Breakthrough May Improve Cancer Vaccines
/0 Comments/in Immunotherapy, Not PCa related, Preclinical Research/by MaxCaRe Trial Expands to Include Veterans
/0 Comments/in Clinical Trial, Metastatic, Phase 1, Phase 2/by MaxNewsletter 4/2025
/0 Comments/in Newsletter/by MaxLAST WEEK TODAY! A summary of what was published on ProstateWarriors.com during the past week Hi, fellow fighters! I’m back on track. This past week was packed with new clinical trial information. I want to highlight the ever-increasing role of AI in drug discovery—we are truly living in a transformative time. As usual, we also have a […]
Phase 1 Trial: Pocenbrodib, A New (AI Based) Approach for mCRPC
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxPhase 1/2 Study: Evofosfamide With Immune Checkpoint Inhibitors for Advanced Cancers
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
abiraterone acetate ADC ADT AI ai in healthcare alphafold antibody-drug conjugate apalutamide artificial intelligence ATM bispecific antibody bone metastases bone metastasis BRCA cancer immunotherapy cancer treatment cancer vaccine clinical trial clinical trials crispr darolutamide drug repurposing drug resistance enzalutamide hormone therapy immune checkpoint inhibitors immunotherapy mcrpc metastatic castration-resistant prostate cancer metastatic hormone-sensitive prostate cancer mHSPC mRNA nanotechnology neuroendocrine prostate cancer oncology oncolytic virus personalized medicine prostate cancer PSMA radioligand therapy radiopharmaceuticals real-world data T-cell therapy targeted drug delivery theranostics
Latest Posts
- Predictive Oncology’s Breakthrough in Drug Repurposing Offers Hope for Patients April 16, 2025
- Phase 1 Soon Recruiting: MK-2400 (Ifinatamab Deruxtecan) for Metastatic Prostate Cancer April 15, 2025
- Newsletter 15/2025 April 13, 2025
- Phase 1 Trial: The COSMYC Trial, ZEN-3694 Combination With BAT April 11, 2025